China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced plans to increase investment in establishing a specialized artificial intelligence (AI) department. The move includes deploying DeepSeek, a Chinese advanced AI model for complex reasoning and natural language processing, to accelerate the development of its T cell engager (TCE) platform with spatial hindrance shielding effect.
AI Strategy
Antengene has been active in AI drug discovery since 2021, backing local AI-enabled drug developer MindRank Ltd as an angel investor. With the deployment of DeepSeek, the company will utilize specific algorithms and AI data collection to integrate and analyze cross-database multi-omics information. This approach aims to effectively sort and select candidate proteins targeting new tumor antigens suitable for TCE, thereby enhancing the development of its TCE platform pipeline.-Fineline Info & Tech
Leave a Reply